Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Chemoembolization in Unresectable Hepatocellular Cancer
NCT00006198Phase 2Unknown
- Sponsor
- National Center for Research Resources
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in hepatocellular carcinoma (HCC), sponsored by National Center for Research Resources. Primary endpoints: Feasibility of chronic thalidomide administration and Toxicity and Overall Safety. Status: unknown.
02
Drugs
thalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00006198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006198.